Overexpression of the ERBB2 proto-oncogene in breast tumours, which occurs in 25 ± 30% of patients, correlates with poor prognosis. In oestrogen receptor (ER) positive breast epithelial cells oestrogens reduce ERBB2 mRNA and protein levels, an eect that is reversed in the presence of anti-oestrogens such as tamoxifen and ICI 182780. Our previous studies have shown that the major eect of oestrogen on ERBB2 expression is at the level of transcription and that this is mediated through a region within the ERBB2 ®rst intron which can act as an oestrogen-suppressible enhancer in ER positive breast cells. In vitro footprinting of the smallest DNA fragment that retained full activity revealed four transcription factor binding sites. We report here that two of these sites are recognized by AP-2 proteins and the other two are bound by a variety of bZIP factors, including CREB and ATF1, with a major complex containing ATFa/ JunD. However, by using ER mutants it is clear that repression occurs essentially o the DNA. Indeed, the essential domain of the ER responsible for repression of the ERBB2 enhancer is a region termed AF2 which is required for the ligand-dependent association of non-DNA binding cofactors. We further demonstrate that one of these ER cofactors, SRC-1, can relieve oestrogen repression of the ERBB2 enhancer and conclude that these data ®t with a model whereby the ER and the ERBB2 enhancer compete for this limiting, non-DNA binding cofactor. Thus, in oestrogenic conditions SRC-1 preferentially binds to the ER which eectively sequesters it thereby reducing enhancer activity, but in antioestrogenic media the cofactor is released from the ER and is therefore available to activate the ERBB2 enhancer. Oncogene (2000) 19, 490 ± 497.
Introduction
The ERBB2 proto-oncogene is a member of the epidermal growth factor receptor (EGFR) family of membrane bound tyrosine kinases. In situ hybridization studies and targeted gene disruption in mice have shown that this protein plays a key role in neural and cardiac development (Lee et al., 1995; Marchionni et al., 1995) . The protein is only expressed at low levels in most normal adult tissues, but is overexpressed in a number of human tumours, including 25 ± 30% of breast carcinomas, where it is a marker of poor prognosis (Slamon et al., 1987; Revillion et al., 1998) . In addition, experiments in vitro and in transgenic mice have shown that overexpression of ERBB2, or its rodent counterpart, c-neu, in breast epithelial cells can result in cellular transformation (DiFiore, 1987; Bouchard et al., 1989; D'Souza et al., 1993) . Taken together these ®ndings have strongly implicated this gene in the pathogenesis of mammary carcinoma and this has led to the development of a therapeutic antibody against ErbB2 which is showing good clinical promise (Nass et al., 1998) thus demonstrating the relevance of these studies to patient care.
We have previously shown that overexpression of ERBB2 in breast tumour-derived cell lines is controlled, at least in part, by the increased activity of its promoter through the binding of an additional DNA binding protein found in overexpressing cells which we showed was related to the developmentally regulated transcription factor, AP-2. Further characterization of this protein has identi®ed a family of three related genes, AP-2a, b and g (Bosher et al., 1996) . All three of these proteins, but particularly AP-2a and g, can activate the ERBB2 promoter and can be found at elevated levels in breast tumour-derived cell lines. We have extended these observations by performing immunohistochemistry on clinical breast specimens with speci®c AP-2 antisera (Turner et al., 1998; Gee et al., 1999) and found AP-2 staining in both adjacent normal and tumour cells. Interestingly, we found that both AP-2a (17% of cases) and AP-2g (84% of cases) are overexpressed in a proportion of tumours with a highly signi®cant correlation (P=0.003) between AP-2 and ErbB2 status being observed in specimens with strong staining for both AP-2a and AP-2g.
Another signi®cant feature of ERBB2 expression control is that oestrogen down-regulates mRNA and protein levels in oestrogen receptor (ER) positive breast epithelial cells (Dati et al., 1990; Read et al., 1990 , Warri et al., 1991 , Antoniotti et al., 1994 . This eect is reversed in the presence of anti-oestrogens such as tamoxifen and ICI 182780; an observation that clearly has signi®cant implications for anti-oestrogenic therapy for breast cancer, particularly in the area of tamoxifen resistance. Work in cell lines has demonstrated that overexpression of ErbB2 in ER positive cells can result in resistance to tamoxifen (Pietras et al., 1995) and studies in patients have also linked ERBB2 overexpression with a poor response to anti-oestrogen therapy (Newby et al., 1997; Revillion et al., 1998) . It is therefore important to understand the molecular mechanism behind the cross talk between these signalling pathways. Our previous studies have con®rmed that the major eect of oestrogen on ERBB2 expression is at the level of transcription and that this is mediated through a 409 bp region within the ERBB2 ®rst intron which can act as an oestrogen-suppressible enhancer in ER positive breast cells. Similarly, in ER negative breast lines, cotransfection of an ER expression plasmid led to repression of enhancer activity in oestrogenic, but not in anti-oestrogenic conditions (Bates and Hurst, 1997) . The data presented here identify the transcription factors capable of interacting with the intron 1 enhancer and show that competition between these factors and the ER for a common, non-DNA binding cofactor is the most likely mechanism behind the repression of ERBB2 expression by oestrogen.
Results

AP-2 and CRE binding proteins interact with the intronic enhancer
We have previously identi®ed a 409 bp region within the ®rst intron of the ERBB2 gene which acted as an oestrogen suppressible enhancer in a number of transfection-based assays and which appears to mediate ER-dependent repression of ERBB2 expression (Bates and Hurst, 1997) . In vitro footprinting of the enhancer had revealed four protected regions, designated FPA-D and, as a ®rst step to further characterizing the action of the enhancer, we sought to identify the transcription factors in breast tumour cells binding at these sites. Oligonucleotides were used to create 20 ± 25 bp probes representing each footprint site individually for use in EMSA assays.
Site A contains a consensus CRE (cAMP binding element; TCGTCAT) which is capable of binding a number of members of the bZIP family of transcription factors (Hurst, 1996) . Upon incubation with nuclear extract, two protein complexes formed on the FPA probe ( Figure 1a , lane 1). We were able to show, with the addition of speci®c antibodies to the EMSA assays, that these complexes represented the binding of CREB dimers (the upper complex) and CREB/ATF1 heterodimers (the lower complex) present in our nuclear extracts ( Figure 1a , lanes 2 ± 4). Site B also resembles a CRE (ACCTCAT) and, as again con®rmed by antibody testing, also bound CREB and CREB/ATF1 complexes, though more weakly (Figure 1a , lanes 6 ± 10, lower complexes). However, the major, slower migrating complex formed on the FPB probe is clearly distinct. Other bZIP factors that have been shown to bind to sequences resembling FPB include the stressactivated factors ATF2 and cJun (Benbrook and Jones, 1994) . By testing further antibodies we demonstrated that, while these particular proteins can bind the FPB probe (see for example ATF2 made in vitro binding FPB, Figure 1b , lanes 13 ± 16) neither protein is a component of the complex detected in breast nuclear extracts (Figure 1b , lanes 6, 7 and 11). Instead we found that the ATF2-related protein, ATFa and the Jun family member, JunD are the major components of this in vivo complex (Figure 1b , lanes 9 and 10). This was further con®rmed by our ability to form an indistinguishable complex on the FPB probe with ATFa/JunD heterodimers synthesized in vitro ( Figure  1b, lanes 1 ± 4) .
The complexes that formed on Sites C and D, which migrated with similar mobility, were characterized by binding site competition, antibodies and comparison with proteins synthesized in vitro (Figure 2 and data not shown). This showed that these complexes were due to the AP-2 family of transcription factors whose interaction with the ERBB2 promoter and upregulation in ERBB2-overexpressing breast tumour lines we have Figure 1 Factors binding to the CRE-like elements in the intron 1 enhancer. (a) EMSA assay in standard buer comparing DNA/ protein complexes formed on the FPA (lanes 1 ± 5) and FPB (lanes 6 ± 10) probes. All lanes contained 1 mg crude nuclear extract from ZR-75-1 cells which was pre-incubated with either control (7) or speci®c antibodies as indicated above each lane. Arrows mark the complexes identi®ed here and from the experiments in B. (b) EMSA assay showing the DNA/protein complexes formed on the FPB probe. Lanes 1 ± 4 contained an optimized amount of in vitro co-translated ATFa/JunD; lanes 5 ± 12 contained 1 mg/lane crude nuclear extract from ZR-75-1 cells; lanes 13 ± 16 contained an optimized amount of in vitro translated ATF2. Proteins were pre-incubated with either control serum (7) or speci®c antibodies as indicated above each lane. To optimize the formation of the ATFa/JunD complex, 10 mM MgCl 2 was added to the standard binding reactions. For both panels, only DNA/protein complexes are shown and complexes marked* indicate the migration of interactions with non-speci®c DNA binding proteins present either in the nuclear extract or the rabbit reticulocyte lysate Oncogene Transcriptional cofactor competition between ER and ERBB2 SP Newman et al previously studied in some detail (Bosher et al., 1995 (Bosher et al., , 1996 . The core AP-2 binding sequence in these two sites is virtually identical (CTG/CCAGGGCA) and diverges somewhat from the classical consensus AP-2 binding motifs (GCCN3/4GGC). Thus, like the ERBB2 promoter site, both FPC and FPD are comparatively weak AP-2 binding sites, nevertheless they clearly represent functional sites (see below).
During the initial footprinting analysis and the EMSA characterization of the transcription factors described here, it was clear that all the enhancer binding proteins were equally abundant in extracts from cells grown in the presence of oestrogen or antioestrogen (Bates and Hurst, 1997 ; data not shown). There is therefore no simple explanation for the altered activity of the enhancer in the two conditions. The activity of many of the factors identi®ed can be modulated by phosphorylation, but speci®c antibodies to phosphorylated forms of CREB and ATFa also failed to detect any dierences by Western blotting. Similarly, we also failed to detect any change in the phosphorylation status of the SAPK/JNK kinase family which can activate JunD. Our ability to detect similar amounts of the phosphorylated (activated) forms of these proteins (data not shown) suggests that repression of ERBB2 expression by oestrogen is mediated by some other mechanism.
Sites B, C and D are required for optimal enhancer activity During our initial characterization of the ERBB2 intronic enhancer we noted that further deletion of the 409 bp element led to loss of oestrogen regulation indicating that the majority of the binding transcription factors were required for enhancer activity. In order to examine this in more detail we made a series of mutant enhancers where binding to each footprinted site in turn was abolished by the introduction of 3 bp changes within the core binding elements (see Materials and methods). Each of the mutants was checked by DNA sequencing and by footprinting to con®rm that the altered site was unable to bind nuclear protein. The wild-type and mutant enhancers were then used to create a new series of CAT reporter constructs, p86(X/ S)CAT, containing a minimal (+40/786) ERBB2 promoter which lacks the AP-2 site at 7200 and which alone is not repressed by oestrogen (Bates and Hurst, 1997 ; data not shown). These reporter plasmids were transfected into the oestrogen receptor positive breast tumour line ZR75-1 and CAT activity was compared in cells maintained in the presence of either b-oestradiol (normal medium) or the anti-oestrogen, ICI 182780. As shown in Figure 3 , the wild-type enhancer is suppressed 4.5-fold in the presence of boestradiol.
The eect of mutating the individual factor binding sites is most clearly seen in the derepressed (plus antioestrogen) condition. Loss of FPA led to a modest increase in enhancer activity while decreases in activity were seen with the FPC and FPD mutants. However, mutation of FPB resulted in the loss of enhancer function. Thus the majority of enhancer activity is due to the binding of ATFa/JunD and in this regard it is interesting to note that it has been shown that while ATFa homodimers are very weak transcription factors, heterodimerization with any of the Jun family members produces a potent activator (Chatton et al., 1994) . Versions of the wild-type (wt) p86(X/S)CAT reporter were made containing 3 bp mutations within each of the four enhancer footprint (FP) sites to generate FPAm, FPBm, FPCm and FPDm. The activity of these constructs was tested in transfection assays in ER positive ZR75-1 cells using 2.5 mg/plate of each reporter as indicated and subsequently maintaining the cells in either oestrogenic or anti-oestrogenic media. CAT readings were normalized to the level of activity of the wt construct in oestrogenic conditions which was set at 1 Nevertheless, all of the mutant enhancer constructs, even FPBm, remained at least twofold suppressible by b-oestradiol (Figure 3) , indicating that the presence of three factor binding sites may compensate for the loss of any one in this assay. Previously we have examined deletions of the 409 bp enhancer that retained sequences spanning either FPA plus FPB or FPC plus FPD (Bates and Hurst, 1997) . Neither of these was regulated by oestrogen but to test this further we have generated constructs containing single and multiple copies of footprint sites, particularly concentrating on the most active site, FPB. However, none of these chimeric enhancers was suppressed by oestrogen either (data not shown). Taken together these data indicate that no single factor binding site totally mediates the oestrogen repression eect. Consequently, to try to gain some insight into the mechanism of repression we turned our attention to the ER itself.
Oestrogen repression requires AF2 of the ER
In order to determine which regions of the ER were required to eect oestrogen suppression of the ERBB2 enhancer, we used an alternative transfection strategy employing the breast tumour line MDA MB 453 which lacks detectable ER. We had previously shown that cotransfection with an expression construct for human ER resulted in repression of the activity of our reporter constructs in the presence of oestrogen and relief of repression in the presence of anti-oestrogen (Bates and Hurst, 1997) . Using the p86(X/S)CAT reporter plasmid, we could show that the highly homologous ER from mouse (MOR) was also able to repress activity fourfold in the presence of b-oestradiol compared to ICI 182780 (Figure 4b) , thus acting at least as well as the human ER in this assay. Oestrogen receptors have a number of de®ned functional domains (see summary, Figure 4a ): an N-terminal, ligand-independent activation domain (AF1), a central DNA binding domain (DBD) consisting of two Zinc ®ngers and a C-terminal ligand binding domain (LBD) which, on binding oestrogen but not anti-oestrogen, forms the main activation domain (AF2). As presented in Figure 4b , we tested a series of MOR mutants in our suppression assay, where each of these domains had been removed or rendered inactive. Signi®cantly, mutation within the In each case cells were transfected with 2.5 mg/plate of the p86(X/S)CAT reporter plus 0.2 mg of an ER expression construct as indicated and subsequently maintained in either oestrogenic or antioestrogenic media. CAT readings were compared to the level of the activity observed with the reporter construct alone with no added ER (not shown) which was set at 100% Oncogene Transcriptional cofactor competition between ER and ERBB2 SP Newman et al DBD alone (MOR C241A/C244A) still produced a protein capable of eciently repressing the ERBB2 enhancer. This result demonstrates that DNA contacts are not important for the repression mechanism and that the process occurs o the DNA. In contrast, removal of the entire C-terminus (MOR 1 ± 339) led to complete loss of the repression activity showing both the importance of the LBD and AF2 for repression and that the AF1 domain alone is not sucient to repress the ERBB2 enhancer. This conclusion was further emphasized using a construct lacking AF1 (MOR 182 ± 599) which was at least as active as the wild-type protein in mediating ERBB2 repression (Figure 4b) .
Domains removed/inactivated
The formation of AF2 is dependent upon the integrity and alignment across the LBD of helix 12, a C-terminal amphipathic a-helix (Danielian et al., 1992; Brzozowski et al., 1997) . Abolishing AF2 activity by removal of the helix 12 sequences (residues 538 ± 552) from the active construct MOR 182 ± 599 resulted in a protein which was unable to suppress the activity of the intron 1 enhancer in our assay (Figure 4b , 182 ± 559/DH12). In conclusion therefore, an intact AF2 domain is essential for ER repression of ERBB2 expression.
ER cofactors also activate the ERBB2 enhancer
The conformational change that occurs in helix 12 on binding of ligand results in the recruitment of a number of dierent cofactors, many of which have now been cloned (McKenna et al., 1999) . The precise role of some of these factors remains to be determined, but three related 160 kDa proteins (p160 family) named SRC-1/NcoA-1, TIF2/GRIP2 and AIB1/ SRC3/ACTR/RAC3/pCIP clearly potentiate the transcriptional activity of the ER and indeed several other nuclear receptors (McKenna et al., 1999) . This interaction, which is tightly ligand-dependent, is mediated by LXXLL motifs present in all of these proteins (Heery et al., 1997; Torchia et al., 1997) . If these factors are also required for the activity of the ERBB2 enhancer, it is conceivable that the activated ER may compete for their binding and thereby repress ERBB2 expression.
To test this hypothesis we examined the ability of expression constructs for SRC-1 to prevent repression of the ERBB2 enhancer construct in ZR75-1 cells in the presence of b-oestradiol. As shown in Figure 5a , we found a dose-dependent increase in reporter activity in our co-transfection experiments such that, at the higher doses of the SRC-1 expression construct, the activity of the ERBB2 enhancer was similar to that observed in anti-oestrogenic conditions without added SRC-1 (Figure 5a , compare columns 2 and 5). A reporter construct containing the 786 ERBB2 promoter alone was not aected by exogenous SRC-1 expression (data not shown). These results demonstrate that overexpression of SRC-1 can restore the activity of the ERBB2 enhancer in oestrogenic media. They also indicate that the levels of endogenous SRC-1 are limiting under these conditions as also evidenced by the fact that the activity of the ERBB2 enhancer in antioestrogenic, unrepressed conditions can be further increased by co-transfection of the SRC-1 construct (Figure 5a , compare columns 2, 4 and 6). We conclude that SRC-1 is either directly potentiating the activity of the enhancer or is displacing SRC-1 itself, or related factors, from the ER which are then capable of binding to the enhancer.
We also examined the ability of the related cofactors TIF2 and AIB1 to relieve repression by oestrogen and found that neither had signi®cant activity in this assay (see Figure 5b) indicating that SRC-1 is the most potent. To investigate this further we analysed a mutant version of SRC-1 that is incapable of binding to the ER for its ability to potentiate ERBB2 enhancer activity. As shown in Figure 6a , SRC-1*, where all the ER interaction motifs have been mutated (Heery et al., 1997) , although less active than the wild-type protein, was still able to relieve oestrogen suppression of the enhancer. In addition, we also assessed the activity of a Figure 5 The SRC-1 cofactor can relieve oestrogen repression of the ERBB2 enhancer. (a) ZR75-1 cells were transfected with 2.5 mg/plate of the p86(X/S)CAT reporter alone (columns 1 and 2) or plus of an expression construct for SRC-1 at 0.2 mg/plate (columns 3 and 4) or 0.5 mg/plate (columns 5 and 6). Cells were subsequently maintained in either oestrogenic (10 78 M 17-boestradiol) or anti-oestrogenic (10 77 M ICI 182780) media as indicated. CAT readings were normalized to the level of activity of the reporter construct alone in oestrogenic conditions which was set at 1. (b) ZR75-1 cells were transfected with p86(X/S)CAT as in (a) either alone (7) or with the addition of 0.5 mg/plate of expression vectors for either TIF2 or AIB1 as indicated. Higher inputs of either expression plasmid did not increase expression levels mutant of SRC-1 that lacks the domain (AD1) required for interaction with p300/CBP (Torchia et al., 1997) . This protein was largely unable to prevent oestrogen repression of the ERBB2 enhancer ( Figure  6b ). Taken together, these data indicate that, rather than displacing another cofactor, SRC-1 is directly recruited by the ERBB2 enhancer where its interaction with p300/CBP (or another AD1-interacting protein) is required for full enhancer activity.
Discussion
From the data presented here, we propose that the mechanism of repression of the ERBB2 enhancer by the oestrogen-bound ER is due to competition for limiting coactivators of the p160 family. Thus, in the presence of oestrogen, the AF2 domain in ER is formed which provides a strong binding site for p160 proteins, eectively sequestering them. Addition of anti-oestrogen however results in the release of coactivators from ER making them available to activate other transcription units including the ERBB2 intronic enhancer. In support of this model, we have demonstrated that the AF2 domain/helix 12, required for ligand-dependent ER-coactivator interaction, was essential for enhancer suppression by the ER (Figure  4 ). Other mutants, including one unable to bind DNA, still possessed essentially wild-type repression activity as they have an intact AF2 and are still able therefore to sequester coactivators in the presence of oestrogen. Furthermore, the ectopic expression of the p160 coactivator SRC-1 was shown to relieve repression in the presence of oestrogen (Figure 5a ) as would be expected if it were a limiting factor.
We have explored the possibility that exogenous SRC-1 could be displacing another factor from the ER which is required for optimal enhancer functioning, but this seems unlikely given that a mutant which is unable to bind ER (SRC-1*) is still able to relieve enhancer suppression. This also suggests that the interaction with the enhancer does not require the LXXLL motifs, though these may lie close to the binding domain as activity is clearly reduced compared to wild-type SRC-1 (Figure 6a ). We have also tested the capacity of the other p160 proteins to relieve oestrogen repression but both TIF2 and AIB1 showed very weak activity (Figure 5b ). We conclude therefore that SRC-1 is the most potent cofactor in our assay and therefore likely to be acting directly at the ERBB2 enhancer. Moreover both SRC-1 and TIF2, although widely expressed, have previously been identi®ed as competable, limiting factors particularly in the context of the squelching of progesterone receptor transactivation in the presence of ectopic ER expression (Onate et al., 1995; Voegel et al., 1996) . Signi®cantly, both proteins are expressed at very modest levels in most breast tumour derived cell lines (Anzick et al., 1997; Berns et al., 1998) and levels of SRC-1 are also particularly low in patients who fail to respond to tamoxifen therapy (Berns et al., 1998) .
Repression by ligand-bound nuclear receptors (NRs) of other transcription factors, notably AP-1, is a well-known biological phenomenon which allows cross-talk between dierent regulatory pathways resulting in ®ne-tuned switching between cellular proliferation and dierentiation, particularly during development (Saatcioglu et al., 1994) . The molecular mechanism behind this has been suggested to involve an inhibition, by ligand-bound receptors, of JNK/ SAPK signalling resulting in reduced activation of Jun and ATF2 family proteins (Caelles et al., 1997 ). An alternative explanation has been that ligand-bound receptors and Fos/Jun proteins compete for the same limiting cofactors, particularly members of the CREBbinding protein (CBP)/p300 family of proteins (Kamei et al., 1996) . We found no evidence of changes in JNK/SAPK activation (data not shown) but the Figure 5a either alone (7) or with the addition of 0.5 mg/plate of expression vectors for SRC-1 mutants as indicated. (a) Optimal interaction between SRC-1 and the ER is not required for relief of enhancer suppression. SCR1* lacks LXXLL motifs. (b) The p300/CBP binding domain in SRC-1 is required for relief of enhancer repression in oestrogenic media. DAD1 lacks the p300/CBP interaction domain model we propose to account for repression of ERBB2 does closely resemble the second mechanism. A major role of the p160 proteins appears to be to help recruit the transcriptional cointegrators p300/ CBP to AF2 (McKenna et al., 1999) and it also seems that SRC-1 may play a similar role at the ERBB2 intronic enhancer as a mutant form, DAD1, lacking the p300/CBP binding domain failed to inhibit oestrogen repression (Figure 6b) . Consequently, the overall molecular events may be very similar to those described for transrepression between NRs and AP1 (Kamei et al., 1996) although in this system we have apparently identi®ed a distinct, competed cofactor (SRC-1 instead of p300/CBP). This may merely re¯ect the relative levels of these proteins in the dierent cell types assayed as indicated by the fact that addition of p300/CBP expression vectors to our transfection assays, either alone or with sub-optimal levels of SRC-1, failed to elicit any eect (unpublished data). However, it also remains possible that the AD1 region may be important for other reasons; it may recruit as yet unidenti®ed cofactors essential for this enhancer to function or it may provide the SRC-1 interaction domain with the ERBB2 enhancer.
This last point highlights the remaining piece of the puzzle: how does SRC-1 interact with the ERBB2 enhancer? Although originally thought to act solely on NRs, SRC-1 has been reported to interact with and modestly coactivate other transcription factors including cFos and cJun , SRF and the p50 subunit of NFkB . In the present context the result with cJun is potentially signi®cant as the related JunD protein was shown to bind as a dimer with ATFa to the FPB site within the ERBB2 enhancer (Figure 1) . However, mutation analysis showed that although the FPB site contributed the majority of the activity of the enhancer, reporter constructs lacking FPB were still suppressed by oestrogen (Figure 3) . Moreover, a similar series of experiments comparing the activity of the mutants +/7 SRC-1 rather than +/7 oestrogen produced a virtually identical result to the graph presented in Figure 3 (unpublished results); that is, all the mutants were still activated at least twofold by ectopic SRC-1 in the presence of oestrogen. This ®nding underlines the link between oestrogen repression and response to SRC-1 but also shows that no single footprinted site within the ERBB2 enhancer mediates either of these eects. We have also tried to create oestrogen-suppressible enhancers using multiple copies of single and paired footprint regions without success. To date we have also been unable to show any direct interaction, even in vitro, between SRC-1 (or ER) and ATFa or AP-2, the other factor that binds the enhancer (unpublished results). One possible explanation for these results may be that the factors binding the ERBB2 enhancer may provide a common interaction surface which allows them collectively to recruit SRC-1. Such a strategy is believed to be used by the so-called enhanceosome of interferon (IFN)-b in the recruitment of p300/ CBP during transcriptional activation of the gene (Merika et al., 1998) and has also been proposed to contribute to the functioning of other enhancers (Carey, 1998) .
Materials and methods
Electromobility shift assays (EMSA)
Nuclear extracts from ZR75-1 cells were made as previously described (Bosher et al., 1995) . Proteins were translated in vitro using the Promega T'n'T system using cDNA clones for ATF2, ATFa2 and JunD cloned into the T7PLINK vector (Livingstone et al., 1995) . Proteins were incubated for 2 h at 48C in standard binding buer (20 mM HEPES, pH 8.0; 150 mM KCl; 10% glycerol; 2 mM DTT) with appropriate antibodies as follows: aCREB and aATF1 as described (Hurst et al., 1990) ; aATFa was the 1A7 monoclonal antibody (Bocco et al., 1996) ; aATF2 was the N-terminal antibody as described (Livingstone et al., 1995) ; the Jun family and the AP-2 antibodies were all purchased from Santa Cruz Biotechnology (sc-45, sc-73, sc-74 and sc-184) . Double stranded oligonucleotide probes to the *20 bp regions protected by each footprint (Bates and Hurst, 1997) were end-labelled and incubated with the protein/antibody mixes and separated on non-denaturing gels as described elsewhere (Bosher et al., 1995) .
Transient transfection assays
The p86(X/S)CAT reporter is a derivative of the p300(X/ S)CAT construct described previously (Bates and Hurst, 1997) with the intron 1 enhancer cloned into pCATbasic (Promega) and a minimal ERBB2 promoter (truncated at the BssHII site at 786) driving expression of CAT. All MOR expression constructs were cloned in the vector pMT2 and have been described previously (Lahooti et al., 1994) with the exception of the MOR 182 ± 599/DH12 mutant which was generated by replacing the 3' Xbal/EcoRI fragment of pMT2MOR182 ± 599 with the equivalent fragment from pJ3MORDH12 (Danielian et al., 1992) . The SRC-1 expression clones were in pSG5 and all based on the SRC-1e isoform and expressed at comparable levels (Kalkhoven et al., 1998; Bevan et al., 1999) . AIB1 and TIF2 expression constructs have been described elsewhere (Anzick et al., 1997; Voegel et al., 1996) . Cell monolayers were transiently transfected and subsequently hormonally manipulated as described previously (Bates and Hurst, 1997) . Transfection eciencies were internally controlled by including a bgalactosidase expression vector and all CAT values are presented after correction for b-galactosidase activity. It should be noted that no signi®cant variation in bgalactosidase activity was observed between cells incubated under the dierent hormonal conditions indicating that during the time course of our assays there was no alteration in growth of the cells. Moreover, normal serum contains oestrogens and we have merely ensured an equal, physiological level in all experiments by adding 17-b-oestradiol to 10 78 M. All experiments were performed on duplicate plates of cells and repeated at least three times to allow the calculation of standard deviations of the mean displayed as error bars.
Mutagenesis of the ERBB2 enhancer
Mutagenesis was performed on the 409 bp enhancer subcloned in pBluescript. A PCR-based approach (QuickChange site-directed mutagenesis kit; Stratagene) was used to mutate the core binding sites as follows: FPA (CGTCA to CTCCC), FPB (CCTCA to CTCCC) and FPD (CTGGAGG to CTTAATG). FPC was mutated by taking advantage of the PstI restriction site in the middle of the binding site to delete the central 4 bp, a strategy we have previously used to abolish binding at the AP-2 site within the ERBB2 promoter (Hollywood and Hurst, 1993) . To ensure that the binding sites had been destroyed, mutant versions were sequenced and checked for in vitro footprinting activity as detailed elsewhere (Bates and Hurst, 1997) before being recloned into the p86CAT reporter.
